Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 603 All time
- Disclosed funding
- $28.7B 480 disclosed amounts
- Median round
- $17M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| N NucleraCompany profile Provides rapid access to functional proteins through benchtop eProtein Discovery System Provides rapid access to functional proteins through benchtop eProtein Discovery System | $12M | Series C+ | Biotech | United Kingdom | Investors | |
| S Provides enterprise informatics platform for laboratories | Undisclosed | Undisclosed | Biotech, Enterprise software | United States | Investors | |
| CB AI platform for accelerated drug discovery and development | $25M | Series A | Biotech, AI | United States | Investors | |
| P Develops AI-driven drug discovery for proximity therapeutics | $80M | Undisclosed | Biotech | United States | Investors | |
| AB Avenue BiosciencesCompany profile Develops high-throughput protein engineering technology for biologics manufacturing Develops high-throughput protein engineering technology for biologics manufacturing | $5.7M | Seed+Seed | Biotech | United States | Investors | |
| F FluoSpheraCompany profile Develops human-based preclinical platform for drug safety and efficacy testing Develops human-based preclinical platform for drug safety and efficacy testing | €1.2M | Undisclosed | Biotech | Switzerland | Investors | |
| VT Develops intelligent, logic-gated therapeutics for solid tumors | $61M | Series A | Biotech | China | Investors | |
| N Develops implant for treating articular cartilage defects in the knee | $4.1M | Seed2Seed | Biotech | United States | Investors | |
| V Provides intelligent software platforms for oncology care | $43M | Undisclosed | Biotech, Healthtech | United States | Investors | |
| MT Mirador TherapeuticsCompany profile Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases | $250M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Delix Therapeutics, Alethio Therapeutics, Estuary Biotherapeutics
27rounds6led - 2Eli Lilly and Company
Oyster Therapeutics, BigHat Biosciences, Circle Pharma, Inc.
16rounds0led - 3Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
16rounds1led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
16rounds1led - 5OrbiMed
Dren Bio, Star Therapeutics, Leal Therapeutics
12rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.